

**Response to Supplemental Restriction Requirement**  
**Application No. 10/694,183**

In response to the election of optional or additional components, Applicants elect the vasoactive agents, as defined in claim 46, with traverse. These vasoactive agents include a potassium channel activator, a calcium blocker, an  $\alpha$ -blocker, a  $\beta$ -blocker, adenosine, an ergot alkaloid, a vasoactive intestinal peptide, a dopamine agonist, an opioid antagonist, a prostaglandin and an endothelin antagonist.

In response to the election of a specifically named disease, Applicants elect the method of treating pulmonary hypertension, with traverse.

An early and favorable consideration and allowance of the pending claims is respectfully requested.

Respectfully submitted,



Belinda M. Lew, Ph.D.  
Registration No. 53,212

Dated: August 11, 2006  
Wilmer Cutler Pickering Hale and Dorr LLP  
1875 Pennsylvania Avenue, NW  
Washington, DC 20006  
Phone: (202) 663-6029